Review of guidelines and the literature in the treatment of acute bronchospasm in asthma

Pharmacotherapy

Volumn 26, Issue 9 II, 2006, Pages

  Blake, Kathryn ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

2 agonist; Acute bronchospasm; Albuterol; Asthma; Corticosteroids; Delivery devices; Ipratropium bromide; Levalbuterol; Treatment

Indexed keywords

AMINOPHYLLINE; ANESTHETIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; HALOTHANE; IPRATROPIUM BROMIDE; ISOFLURANE; LEVALBUTEROL; MAGNESIUM SULFATE; PREDNISONE; SALBUTAMOL; THEOPHYLLINE;

ABSENTEEISM; AGE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONFERENCE PAPER; COOPERATION; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; EMERGENCY WARD; FORCED EXPIRATORY VOLUME; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LUNG FUNCTION; METERED DOSE INHALER; PRACTICE GUIDELINE; QUALITY OF LIFE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; ALBUTEROL; ASTHMA; BRONCHIAL SPASM; BRONCHODILATOR AGENTS; HOSPITALIZATION; HUMANS; IPRATROPIUM; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 33748093800     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.9part2.148S     Document Type: Conference Paper

References (53)

1. National Heart, Lung, and Blood Institute. National Institutes of Health. National asthma education and prevention program. Expert panel report 2: guidelines for the diagnosis and management of asthma. NIH publication no. 97-4051. Bethesda, MD: U.S. Department of Health and Human Services, July 1997.
2. National Institutes of Health. Global strategy for asthma management and prevention. Global initiative for asthma. NIH publication no. 02-3659. Bethesda, MD: U.S. Department of Health and Human Services, January 1995, updated 2002 and 2003.
3. American Lung Association, Epidemiology and Statistics Unit, Research and Scientific Affairs. Trends in asthma morbidity and mortality. March 12, 2004. Available from www.lungusa.org/data. Accessed June 27, 2006.
4. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol 2000;106:493-9.
5. Centers for Disease Control and Prevention. 2004 national health interview survey. Available from www.cdc.gov. Accessed March 18, 2006.
6. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States [see comments]. N Engl J Med 1992;326:862-6.
7. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3-8.
8. National Heart, Lung, and Blood Institute. National Institutes of Health. Morbidity and mortality: 1996 chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: U.S. Department of Health and Human Services, 1996.
9. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-9.
10. Suissa S, Ernst P, Bolvin F, et al. A cohort analysis of excess mortality in asthma and in the use of inhaled beta2-agonists. Am J Respir Crit Care Med 1994;149(3 pt 1):604-10.
11. Kallenbach JM, Frankel AH, Lapinsky SE, et al. Determinants of near fatality in acute severe asthma. Am J Med 1993;95:265-72.
12. Rodrigo C, Rodrigo G. Assessment of the patient with acute asthma in the emergency department. Chest 1993;104:1325-8.
13. Greenberger PA, Miller TP, Lifschultz B. Circumstances surrounding death from asthma in Cook County (Chicago) Illinois. Allergy Proc 1993;14:321-6.
14. O'Hallaren MT, Yunginger JW, Offord KP, et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991;324:359-63.
15. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
16. Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med 1999;160:211-15.
17. Rodrigo C, Rodrigo G. Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma. Chest 1998;113:593-8.
18. Strauss L, Hejal R, Galan G, Dixon L, McFadden ER Jr. Observations on the effects of aerosolized albuterol in acute asthma. Am J Respir Crit Care Med 1997;155:454-8.
19. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest 2004;125:1081-102.
20. Robertson CF, Smith F, Beck R, Levison H. Response to frequent low doses of nebulized salbutamol in acute asthma. J Pediatr 1985;106:672-4.
21. Schuh S, Parkin P, Rajan A, et al. High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989;83:513-18.
22. Schuh S, Reider MJ, Canny G, et al. Nebulized albuterol in acute childhood asthma: comparison of two doses. Pediatrics 1990;86:509-13.
23. Lin RY, Sauter D, Newman T, Sirleaf J, Walters J, Tavakol M. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med 1993;22:1847-53.
24. Rudnitsky GS, Eberlein RS, Schoffstall JM, Mazur JE, Spivey WH. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med 1993;22:1842-6.
25. Shrestha M, Parupia H, Andrews B, et al. Metered-dose inhaler technique of patients in an urban ED: prevalence of incorrect technique and attempt at education. Am J Emerg Med 1996;14:380-4.
26. Nowak RM, Emerman CL, Schaefer K, Disantostefano RL, Vaickus L, Roach JM. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004;22:29-36.
27. Keir S, Page C, Spina D. Bronchial hyperresponsiveness induced by chronic treatment with albuterol: role of sensory nerves. J Allergy Clin Immunol 2002;110:388-94.
28. Keir SD, Spina D, Page CP. A comparison of the effects of RS-and S-albuterol on airway responses in immunized guinea pigs [abstr]. Am J Respir Crit Care Med 1999;159:A875.
29. Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Pulm Pharmacol 1994;7:367-76.
30. Waldeck B. Enantiomers of bronchodilating beta2-adrenoceptor agonists: is there a cause for concern? J Allergy Clin Immunol 1999;103(5 pt 1):742-8.
31. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998;11:1-6.
32. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle. J Allergy Clin Immunol 2005;116:65-72.
33. Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001;124:478-84.
34. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998;53:347-54.
35. Baramki D, Koester J, Anderson AJ, Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;109:449-54.
36. Nowak R, Emerman C, Hanrahan JP, et al, for the XOPENEX Acute Severe Asthma Study Group. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006;24:259-67.
37. Qureshi F, Zaritsky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005;46:29-36.
38. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003;143:731-6.
39. Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998;339:1030-5.
40. Plotnick LH, Ducharme FM. Should inhaled anticholinergics be added to beta2-agonists for treating acute childhood and adolescent asthma? A systematic review. BMJ 1998;317:971-7.
41. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000;161:1862-8.
42. Rowe BH, Edmonds ML, Spooner CH, Diner B, Camargo CA Jr. Corticosteroid therapy for acute asthma. Respir Med 2004;98:275-84.
43. Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 2000;343:689-94.
44. Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA 1999;281: 2119-26.
45. Blake K. Theophylline. In: Murphy S, Kelly HW, eds. Pediatric asthma. New York: Marcel Dekker, Inc., 1999:363-431.
46. Yung M, South M. Randomised controlled trial of aminophylline for severe acute asthma. Arch Dis Child 1998;79:405-10.
47. Ream RS, Loftis LL, Albers GM, Becker BA, Lynch RE, Mink RB. Efficacy of IV theophylline in children with severe status asthmaticus. Chest 2001;119:1480-8.
48. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127;335-71.
49. Kelly HW. Pharmacology of inhaled glucocorticoids: comparative properties. Immunol Allergy Clin North Am 1999;19:725-38.
50. Everard ML, Clark AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child 1992;67:586-91.
51. Iies R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999;81:163-5.
52. Wildhaber JH, Devadason SG, Hayden MJ, Eber E, Summers QA, LeSouëf PN. Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers. Pediatr Pulmonol 1997;23:212-16.
53. Schuh S, Johnson DW, Stephens D, Callahan S, Winders P, Canny GJ. Comparison of albuterol delivered by a metered-dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr 1999;135:22-7.